|
Medical device maker Covidien PLC has signed a definitive agreement to acquire Freemont, Calif.-based CV Ingenuity during the first quarter of 2013, the company announced Wednesday.
more
By PBN Staff
|
|
(Updated, 10:45 a.m.) A federal judge accepted Amgen Inc.’s plea agreement on a charge that it misbranded its anemia drug Aranesp, putting to rest a five-year probe of the company’s marketing practices.
more
By Christie Smythe |
|
Rhode Island is set to receive $647,722 as part of a $42.9 million national settlement with drug maker Pfizer Inc. for the unlawful promotion of its drugs Zyvox and Lyrica.
more
By PBN Staff
|
|
Amgen Inc., one of the world’s largest biotechnology companies, has agreed to buy genetic-testing company deCode Genetics Inc. for $415 million, Amgen announced Monday.
more
By PBN Staff
|
|
Seven months after the initial groundbreaking, the University of Massachusetts Dartmouth celebrated the end of the first stage of construction of the Massachusetts Accelerator for Biomanufacturing with a “topping off ceremony” on Thursday in Fall River.
more
By PBN Staff
|
|
Maolin Guo, associate professor of chemistry and biochemistry at the University of Massachusetts Dartmouth, landed a $400,000 research grant from the National Science Foundation to support the development of a molecular imaging probe for cell research.
more
By PBN Staff
|
|
The University of Rhode Island plans to increase its presence in the state’s capital city, according to President David M. Dooley, as part of a strategy to better prepare its students for success as well as help Rhode Island’s economy grow out of the hole it is in.
more
By PBN Staff
|
|
Covidien PLC’s BIS Brain Monitoring System earned a recommendation from the U.K.-based National Institute for health and Clinical Excellence.
more
By PBN Staff
|
|
The 2012 meeting of the Greater Providence Chamber of Commerce, held Monday at the R.I. Convention Center, made news that could re-shape the region’s economy.
more
By PBN Staff
|
|
Medical technology maker Covidien PLC reported fourth-quarter earnings of $461 million, or 95 cents per diluted share, a rise of 2.2 percent from the $451 million, or 92 cents per diluted share reported during the same period in 2011.
more
By PBN Staff
|